MedTrace Logo

An Open-label Long-term Safety Study of Buntanetap in Participants With AD

NCT07757204 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-08-11

No results posted yet for this study

Summary

This study will examine the long-term safety of buntanetap in participants with AD who have participated in a prior study of buntanetap in AD.

Conditions

  • Alzheimer's Dementia (AD)

Interventions

DRUG

buntanetap/posiphen

buntanetap 30 mg daily

Sponsors & Collaborators

  • Annovis Bio Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-21
Primary Completion
2030-02-21
Completion
2030-05-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07757204 on ClinicalTrials.gov